While there is no standard of care treatment for patients with SCN8A-derived epilepsy, from several published studies, sodium channel blockers like oxcarbazepine (OXC) can provide some seizure protection and are well-tolerated (Gardella et al., 2018; Talwar and Hammer, 2021; Johannesen et al., 2022). The gene discussed is SCN8A; the disease is epilepsy.